REGENERATIVE

Exosomes & birth tissue biologics.

Next-generation regenerative therapies — processed under cGMP conditions in FDA-registered facilities, validated through nanoparticle tracking analysis, and delivered fresh (never frozen) to preserve maximum biological activity.

Schedule a consultation → Common questions

Quality Standards

RegulatoryFDA registered
ProcessingcGMP · 21 CFR 1271
Clean roomsISO 5 · 24/7 monitored
StorageNever frozen
SourceWharton's Jelly MSC
ValidationNTA particle tracking
Safety & production

Regenerative medicine, rigorously processed.

Every product meets the full FDA registration and cGMP processing standards for HCT/Ps — with fresh-processing protocols that preserve biological activity.

FDA registered

FDA Registered Facility

cGMP processing facility with full FDA registration and compliance to 21 CFR Part 1271 for human cells, tissues, and cellular and tissue-based products (HCT/Ps). Quality assurance embedded at every production step.

Never frozen

Fresh, Never Frozen

Birth tissue is processed immediately upon receipt and is never frozen — preserving maximum biological activity, signaling capacity, and growth factor integrity in every finished product.

Next-generation

Next-Generation Biologics

Acellular exosome products and Wharton's Jelly MSC-derived therapies that simplify storage and handling while delivering concentrated bioactive cargo — growth factors, cytokines, and signaling molecules.

Common questions

What to know about regenerative biologics.

What are exosomes? +
Exosomes are extracellular vesicles (30–150 nm) that mediate intercellular signaling through the transfer of proteins, lipids, and nucleic acids between cells. In a therapeutic context, exosomes derived from birth tissue carry bioactive cargo — growth factors, cytokines, and signaling molecules — that modulate inflammation, stimulate angiogenesis, and support tissue regeneration. Unlike cell-based therapies, exosome products are acellular, simplifying storage, handling, and regulatory considerations.
What birth tissue products are available? +
Our regenerative portfolio includes exosome products (NTA-validated for concentration, particle size, and batch consistency), Wharton's Jelly MSC-derived therapies, and fresh-processed placental biologics. All products are processed in ISO 5 classified clean rooms with 24/7 environmental monitoring, inside an FDA-registered cGMP facility. Every batch ships fresh — never frozen — preserving maximum biological activity.
What are the clinical applications? +
Regenerative biologics support a range of wound care and musculoskeletal protocols — including chronic wound healing, inflammation modulation, soft tissue regeneration, and combination therapy alongside allografts and collagen programs. Albacete MedDev provides full operational and compliance infrastructure — documentation support, coding guidance, storage and handling protocols, and clinical education — so your practice can implement these therapies with confidence.
Ready when you are

Add regenerative biologics to your program.

A 30-minute consultation to walk through product selection, clinical protocols, and compliance infrastructure.

Schedule a consultation → Explore the portfolio